Recent Updates
Recently added Catalysts
SRRK Positive Sentiment

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

Friday, September 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Scholar Rock has received FDA approval for ISEMBYLD (apitegromab-mstn), marking it as the first muscle-targeted treatment for spinal muscular atrophy (SMA). This approval applies to both adults and children aged two years and older who are currently on SMN2-targeted therapies. The treatment aims to improve the lives of patients suffering from this debilitating condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • First and only muscle-targeted treatment for SMA.
  • FDA approval signifies a major advancement for SMA patients.
  • Benefits both children and adults aged two and older.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
7.3%
average across 6 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Apitegromab
Phase 3 · Spinal Muscular Atrophy

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted

Frequently Asked Questions

What is ISEMBYLD?

ISEMBYLD (apitegromab-mstn) is the first muscle-targeted treatment for spinal muscular atrophy.

Who can receive ISEMBYLD?

ISEMBYLD is approved for adults and children aged two years and older with SMA.

What does FDA approval mean for ISEMBYLD?

FDA approval signifies that ISEMBYLD is recognized as a safe and effective treatment for SMA.

What condition does ISEMBYLD treat?

ISEMBYLD is designed to treat spinal muscular atrophy (SMA).

ShareAdd on Google
Tags: SRRK Viatris Investor Conferences Healthcare ISEMBYLD apitegromab spinal muscular atrophy FDA approval
Last updated: Sep 11, 2026

Biotech snapshot

Cash runway
$492M liquidity · $23M/mo burn
~20 mo
Low dilution risk
Lead asset
ApitegromabPhase 3
Spinal Muscular Atrophy →

Catalyst track record

+32%
best trade around SRRK's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for SRRK.

See every catalyst's timing & PoA →